ANTX
AN2 Therapeutics, Inc.$5.37-0.09 (-1.65%)Prev Close$5.46·MCap$123.3M·P/E—·Vol116.7K·Yield—
▲
Buys (12M)
1
$11.6K
▼
Sells (12M)
17
$444.7K
◆
Net Activity
Net Seller
$433.1K
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at AN2 Therapeutics, Inc. (ANTX) has been dominated by selling, with 1 insider purchase totaling $11.6K and 17 insider sales totaling $444.7K. The most recent insider transaction was by Readnour Robin Shane (director), who sold $6.7K worth of shares on Sep 11, 2026. AN2 Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $123.3M.
ANTX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Readnour Robin Shane | director | Sell | 1,108 | $6.02 | $6.7K | 624,765 |
| Sep 8, 2026 | Readnour Robin Shane | director | Sell | 16,119 | $6.04 | $97.3K | 630,644 |
| Sep 4, 2026 | Williams Sarah Joanne | officer: Principal Accounting Officer | Sell | 272 | $5.53 | $1.5K | 66,311 |
| Sep 2, 2026 | FitzPatrick Margaret M | director | Buy | 2,098 | $5.53 | $11.6K | 10,708 |
| Aug 19, 2026 | Readnour Robin Shane | director | Sell | 35,402 | $6.01 | $212.7K | 633,867 |
| Jul 10, 2026 | Eizen Joshua M | officer: See Remarks | Sell | 5,945 | $4.17 | $24.8K | 206,554 |
| Jun 2, 2026 | Williams Sarah Joanne | officer: Principal Accounting Officer | Sell | 265 | $4.43 | $1.2K | 66,583 |
| Mar 5, 2026 | Williams Sarah Joanne | officer: Principal Accounting Officer | Sell | 327 | $1.06 | $346.62 | 66,848 |
| Jan 7, 2026 | Chanda Sanjay | officer: Chief Development Officer | Sell | 9,251 | $1.01 | $9.3K | 81,779 |
| Jan 7, 2026 | Day Lucy | officer: Chief Financial Officer | Sell | 8,807 | $1.01 | $8.9K | 80,875 |
| Jan 7, 2026 | Eizen Joshua M | officer: See Remarks | Sell | 24,854 | $1.00 | $25.0K | 159,430 |
| Jan 7, 2026 | Prior Stephen David | officer: Chief Strategy Officer | Sell | 6,462 | $1.01 | $6.5K | 61,944 |
| Jan 5, 2026 | Chanda Sanjay | Chief Development Officer | Sell | 5,956 | $1.01 | $6.0K | 0 |
| Jan 5, 2026 | Day Lucy | Chief Financial Officer | Sell | 8,807 | $1.01 | $8.9K | 0 |
| Jan 5, 2026 | Eizen Joshua M | See Remarks | Sell | 24,854 | $1.00 | $25.0K | 0 |
| Jan 5, 2026 | Prior Stephen David | Chief Strategy Officer | Sell | 6,462 | $1.01 | $6.5K | 0 |
| Nov 4, 2025 | Eizen Joshua M | See Remarks | Sell | 2,819 | $1.14 | $3.2K | 0 |
| Nov 4, 2025 | Prior Stephen David | Chief Strategy Officer | Sell | 765 | $1.14 | $872.10 | 0 |
| Jun 12, 2025 | Leonard Braden Michael | 10% Owner | Sell | 200,000 | $1.09 | $218.0K0.7% OS | 0 |
| Jun 2, 2025 | Easom Eric | Chief Executive Officer | Buy | 10,000 | $1.07 | $10.7K | 0 |
| May 28, 2025 | FitzPatrick Margaret M | Director | Buy | 8,610 | $1.18 | $10.1K | 0 |
| May 28, 2025 | Leonard Braden Michael | 10% Owner | Sell | 2,532,000 | $1.13 | $2.87M9.2% OS | 0 |
| Jan 3, 2025 | Day Lucy | Chief Financial Officer | Sell | 2,957 | $1.34 | $4.0K | 0 |
| Jan 3, 2025 | Eizen Joshua M | See Remarks | Sell | 9,663 | $1.34 | $13.0K | 0 |
| Jan 3, 2025 | Prior Stephen David | Chief Strategy Officer | Sell | 2,029 | $1.34 | $2.7K | 0 |
| Dec 6, 2024 | Readnour Robin Shane | Director | Buy | 55,000 | $1.44 | $79.2K | 0 |
| Nov 27, 2024 | Zakrzewski Joseph S | Director | Buy | 2,000 | $1.40 | $2.8K | 0 |
| Nov 26, 2024 | Readnour Robin Shane | Director | Buy | 37,500 | $1.41 | $52.8K | 0 |
| Nov 19, 2024 | Readnour Robin Shane | Director | Buy | 200,000 | $1.07 | $213.1K0.7% OS | 0 |
| Nov 18, 2024 | Easom Eric | Chief Executive Officer | Buy | 50,000 | $1.00 | $50.0K | 0 |
| Nov 18, 2024 | Zakrzewski Joseph S | Director | Buy | 25,000 | $1.00 | $25.0K | 0 |
| Aug 14, 2024 | Leonard Braden Michael | 10% Owner | Buy | 1,500,000 | $1.04 | $1.56M5.5% OS | 0 |
| Jan 18, 2024 | Zakrzewski Joseph S | Director | Sell | 100,000 | $19.11 | $1.91M | 0 |
| Jan 16, 2024 | Aziz Kabeer | Director | Sell | 100,000 | $19.65 | $1.97M | 0 |
| Jan 12, 2024 | Readnour Robin Shane | Director | Sell | 1,425 | $21.91 | $31.2K | 0 |
| Jan 10, 2024 | Readnour Robin Shane | Director | Sell | 3,669 | $21.93 | $80.4K | 0 |
| Jan 9, 2024 | Krause Kevin Michael | Chief Strategy Officer | Sell | 7,417 | $20.14 | $149.4K | 0 |
| Jan 2, 2024 | Easom Eric | Chief Executive Officer | Sell | 2,777 | $20.09 | $55.8K | 0 |
| Jan 2, 2024 | Krause Kevin Michael | Chief Strategy Officer | Sell | 2,583 | $20.12 | $52.0K | 0 |
| Nov 14, 2023 | Aziz Kabeer | Director | Sell | 1,810 | $16.15 | $29.2K | 0 |
| Sep 29, 2023 | Aziz Kabeer | Director | Sell | 104,773 | $16.27 | $1.70M | 0 |
| Sep 27, 2023 | Aziz Kabeer | Director | Sell | 9,357 | $16.11 | $150.7K | 0 |
| Aug 23, 2023 | Aziz Kabeer | Director | Sell | 7,940 | $16.03 | $127.3K | 0 |
| May 15, 2023 | Easom Eric | Chief Executive Officer | Buy | 10,000 | $5.38 | $53.8K | 0 |
| Nov 10, 2022 | Easom Eric | Chief Executive Officer | Sell | 4,436 | $15.32 | $68.0K | 0 |
| Nov 8, 2022 | Easom Eric | Chief Executive Officer | Sell | 17,166 | $15.60 | $267.8K | 0 |
| Nov 3, 2022 | Easom Eric | Chief Executive Officer | Sell | 35,196 | $15.86 | $558.3K | 0 |
| Oct 31, 2022 | Easom Eric | Chief Executive Officer | Sell | 4,232 | $15.27 | $64.6K | 0 |
| Oct 27, 2022 | Easom Eric | Chief Executive Officer | Sell | 2,607 | $15.18 | $39.6K | 0 |
| Oct 24, 2022 | Easom Eric | Chief Executive Officer | Sell | 9,350 | $15.76 | $147.4K | 0 |
Showing 1–50 of 53
1 / 2
ANTX Insider Buying Activity
The following table shows recent insider purchases of AN2 Therapeutics, Inc. (ANTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | FitzPatrick Margaret M | director | Buy | 2,098 | $5.53 | $11.6K | 10,708 |
| Jun 2, 2025 | Easom Eric | Chief Executive Officer | Buy | 10,000 | $1.07 | $10.7K | 0 |
| May 28, 2025 | FitzPatrick Margaret M | Director | Buy | 8,610 | $1.18 | $10.1K | 0 |
| Dec 6, 2024 | Readnour Robin Shane | Director | Buy | 55,000 | $1.44 | $79.2K | 0 |
| Nov 27, 2024 | Zakrzewski Joseph S | Director | Buy | 2,000 | $1.40 | $2.8K | 0 |
| Nov 26, 2024 | Readnour Robin Shane | Director | Buy | 37,500 | $1.41 | $52.8K | 0 |
| Nov 19, 2024 | Readnour Robin Shane | Director | Buy | 200,000 | $1.07 | $213.1K0.7% OS | 0 |
| Nov 18, 2024 | Easom Eric | Chief Executive Officer | Buy | 50,000 | $1.00 | $50.0K | 0 |
| Nov 18, 2024 | Zakrzewski Joseph S | Director | Buy | 25,000 | $1.00 | $25.0K | 0 |
| Aug 14, 2024 | Leonard Braden Michael | 10% Owner | Buy | 1,500,000 | $1.04 | $1.56M5.5% OS | 0 |
| May 15, 2023 | Easom Eric | Chief Executive Officer | Buy | 10,000 | $5.38 | $53.8K | 0 |
ANTX Insider Selling Activity
The following table shows recent insider sales of AN2 Therapeutics, Inc. (ANTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Readnour Robin Shane | director | Sell | 1,108 | $6.02 | $6.7K | 624,765 |
| Sep 8, 2026 | Readnour Robin Shane | director | Sell | 16,119 | $6.04 | $97.3K | 630,644 |
| Sep 4, 2026 | Williams Sarah Joanne | officer: Principal Accounting Officer | Sell | 272 | $5.53 | $1.5K | 66,311 |
| Aug 19, 2026 | Readnour Robin Shane | director | Sell | 35,402 | $6.01 | $212.7K | 633,867 |
| Jul 10, 2026 | Eizen Joshua M | officer: See Remarks | Sell | 5,945 | $4.17 | $24.8K | 206,554 |
| Jun 2, 2026 | Williams Sarah Joanne | officer: Principal Accounting Officer | Sell | 265 | $4.43 | $1.2K | 66,583 |
| Mar 5, 2026 | Williams Sarah Joanne | officer: Principal Accounting Officer | Sell | 327 | $1.06 | $346.62 | 66,848 |
| Jan 7, 2026 | Chanda Sanjay | officer: Chief Development Officer | Sell | 9,251 | $1.01 | $9.3K | 81,779 |
| Jan 7, 2026 | Day Lucy | officer: Chief Financial Officer | Sell | 8,807 | $1.01 | $8.9K | 80,875 |
| Jan 7, 2026 | Eizen Joshua M | officer: See Remarks | Sell | 24,854 | $1.00 | $25.0K | 159,430 |
| Jan 7, 2026 | Prior Stephen David | officer: Chief Strategy Officer | Sell | 6,462 | $1.01 | $6.5K | 61,944 |
| Jan 5, 2026 | Chanda Sanjay | Chief Development Officer | Sell | 5,956 | $1.01 | $6.0K | 0 |
| Jan 5, 2026 | Day Lucy | Chief Financial Officer | Sell | 8,807 | $1.01 | $8.9K | 0 |
| Jan 5, 2026 | Eizen Joshua M | See Remarks | Sell | 24,854 | $1.00 | $25.0K | 0 |
| Jan 5, 2026 | Prior Stephen David | Chief Strategy Officer | Sell | 6,462 | $1.01 | $6.5K | 0 |
| Nov 4, 2025 | Eizen Joshua M | See Remarks | Sell | 2,819 | $1.14 | $3.2K | 0 |
| Nov 4, 2025 | Prior Stephen David | Chief Strategy Officer | Sell | 765 | $1.14 | $872.10 | 0 |
| Jun 12, 2025 | Leonard Braden Michael | 10% Owner | Sell | 200,000 | $1.09 | $218.0K0.7% OS | 0 |
| May 28, 2025 | Leonard Braden Michael | 10% Owner | Sell | 2,532,000 | $1.13 | $2.87M9.2% OS | 0 |
| Jan 3, 2025 | Day Lucy | Chief Financial Officer | Sell | 2,957 | $1.34 | $4.0K | 0 |
| Jan 3, 2025 | Eizen Joshua M | See Remarks | Sell | 9,663 | $1.34 | $13.0K | 0 |
| Jan 3, 2025 | Prior Stephen David | Chief Strategy Officer | Sell | 2,029 | $1.34 | $2.7K | 0 |
| Jan 18, 2024 | Zakrzewski Joseph S | Director | Sell | 100,000 | $19.11 | $1.91M | 0 |
| Jan 16, 2024 | Aziz Kabeer | Director | Sell | 100,000 | $19.65 | $1.97M | 0 |
| Jan 12, 2024 | Readnour Robin Shane | Director | Sell | 1,425 | $21.91 | $31.2K | 0 |
| Jan 10, 2024 | Readnour Robin Shane | Director | Sell | 3,669 | $21.93 | $80.4K | 0 |
| Jan 9, 2024 | Krause Kevin Michael | Chief Strategy Officer | Sell | 7,417 | $20.14 | $149.4K | 0 |
| Jan 2, 2024 | Easom Eric | Chief Executive Officer | Sell | 2,777 | $20.09 | $55.8K | 0 |
| Jan 2, 2024 | Krause Kevin Michael | Chief Strategy Officer | Sell | 2,583 | $20.12 | $52.0K | 0 |
| Nov 14, 2023 | Aziz Kabeer | Director | Sell | 1,810 | $16.15 | $29.2K | 0 |
| Sep 29, 2023 | Aziz Kabeer | Director | Sell | 104,773 | $16.27 | $1.70M | 0 |
| Sep 27, 2023 | Aziz Kabeer | Director | Sell | 9,357 | $16.11 | $150.7K | 0 |
| Aug 23, 2023 | Aziz Kabeer | Director | Sell | 7,940 | $16.03 | $127.3K | 0 |
| Nov 10, 2022 | Easom Eric | Chief Executive Officer | Sell | 4,436 | $15.32 | $68.0K | 0 |
| Nov 8, 2022 | Easom Eric | Chief Executive Officer | Sell | 17,166 | $15.60 | $267.8K | 0 |
| Nov 3, 2022 | Easom Eric | Chief Executive Officer | Sell | 35,196 | $15.86 | $558.3K | 0 |
| Oct 31, 2022 | Easom Eric | Chief Executive Officer | Sell | 4,232 | $15.27 | $64.6K | 0 |
| Oct 27, 2022 | Easom Eric | Chief Executive Officer | Sell | 2,607 | $15.18 | $39.6K | 0 |
| Oct 24, 2022 | Easom Eric | Chief Executive Officer | Sell | 9,350 | $15.76 | $147.4K | 0 |
ANTX Insiders
Similar Stocks to ANTX
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B